Načítá se...
Tirosine Kinase Inhibitors Adverse Events
The authors discuss dasatinib as a tyrosine kinase inhibitor with cardiovascular toxicity, which Lenihan and Kowey did not include in their article “Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors.”
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3958466/ https://ncbi.nlm.nih.gov/pubmed/24643716 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0397 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|